Plasma HIV-1 RNA Detection Below 50 Copies/mL and Risk of Virologic Rebound in Patients Receiving Highly Active Antiretroviral Therapy | Zendy

Tracey M. Doyle | Zendy; Colette Smith | Zendy; Paola Vitiello | Zendy; Valentina Cambiano | Zendy; Melanie Johnson | Zendy; Andrew Owen | Zendy; Andrew Phillips | Zendy; Anna María Geretti | Zendy

Open Access

Plasma HIV-1 RNA Detection Below 50 Copies/mL and Risk of Virologic Rebound in Patients Receiving Highly Active Antiretroviral Therapy

Author(s) -

Tracey M. Doyle,

Colette Smith,

Paola Vitiello,

Valentina Cambiano,

Melanie Johnson,

Andrew Owen,

Andrew Phillips,

Anna María Geretti

Publication year - 2012

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cir936

Subject(s) - medicine , viral load , antiretroviral therapy , lentivirus , virology , rna , human immunodeficiency virus (hiv) , sida , viral disease , virus , immunopathology , immunology , biology , gene , biochemistry

Plasma human immunodeficiency virus type 1 (HIV-1) RNA suppression <50 copies/mL is regarded as the optimal outcome of highly active antiretroviral therapy (HAART). Current viral load (VL) assays show increased sensitivity, but the significance of RNA detection <50 copies/mL is unclear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research